We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > giroctocogene fitelparvovec

News List

Gene therapy sustains bleeding control in haemophilia A trial EuropeanPharmaceuticalReview
December 15, 2021
Giroctocogene fitelparvovec had a mean annualised bleeding rate (ABR) of just 1.4 percent over two years, with no bleeding events in the first year post infusion.
Pfizer, Sangamo announce updated results of phase 1/2 Alta study of giroctocogene fitelparvovec pharmaceutical-business-review
December 09, 2020
Pfizer and Sangamo Therapeutics, a genomic medicines company, announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec (SB-525 or PF-07055480), an investigational gene therapy for patients with severe hemophilia A.